Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05308264 | Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) | recruiting | Phase 1 / Phase 2 | 86 | Rigel PharmaceuticalsINDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05887167 | Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies | recruiting | Phase 1 | 20 | Joshua Sasine, MD, PhDOTHER | 1 | Aug 10, 2026 |
| clinicaltrials |
| NCT05936359 | A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms | active not recruiting | Phase 1 | 160 | Incyte CorporationINDUSTRY | 9 | Aug 10, 2026 | clinicaltrials |
| NCT05976555 | Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma | recruiting | Phase 1 | 30 | Medical College of WisconsinOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06105554 | Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06285890 | Phase I Study of HC-7366 for Acute Myeloid Leukemia | recruiting | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06607549 | Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)(SOLAR) | recruiting | Phase 1 | 12 | University of UtahOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06823167 | A Phase 1 Study of IM-1021 in Participants With Advanced Cancer | recruiting | Phase 1 | 190 | Immunome, Inc.INDUSTRY | 4 | Aug 10, 2026 | clinicaltrials |
| NCT07221032 | FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma | not yet recruiting | Phase 1 | 12 | Medical College of WisconsinOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07451054 | CD45BE-HSPC + CART-45 Cells | recruiting | Phase 1 | 42 | University of PennsylvaniaOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT00392353 | Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 135 | National Cancer Institute (NCI)NIH | 1 | Aug 7, 2026 | clinicaltrials |
| NCT03504644 | Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 / Phase 2 | 40 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Aug 7, 2026 | clinicaltrials |
| NCT05020444 | TriPRIL CAR T Cells in Multiple Myeloma | active not recruiting | Phase 1 | 16 | Marcela V. Maus, M.D.,Ph.D.OTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT05092451 | Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances | recruiting | Phase 1 / Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT05632380 | ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM) | recruiting | Phase 1 / Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07629726 | A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms | recruiting | Phase 1 / Phase 2 | 72 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07661537 | A Clinical Study of SHR-3079 in B-cell Non-Hodgkin Lymphoma | recruiting | Phase 1 | 90 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07751991 | A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML | recruiting | Phase 1 | 40 | Charm TherapeuticsINDUSTRY | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07753148 | Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation | not yet recruiting | Phase 1 | 52 | Regeneron PharmaceuticalsINDUSTRY | 0 | Aug 7, 2026 | clinicaltrials |
| NCT04077307 | A Study in Leukemia Patients With Karonudib(MAATEO) | recruiting | Phase 1 | 50 | Thomas Helleday FoundationOTHER | 3 | Aug 6, 2026 | clinicaltrials |
| NCT05535244 | A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma(CAMMA 2) | active not recruiting | Phase 1 / Phase 2 | 90 | Hoffmann-La RocheINDUSTRY | 8 | Aug 6, 2026 | clinicaltrials |
| NCT05753501 | Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies | active not recruiting | Phase 1 | 135 | AbbVieINDUSTRY | 9 | Aug 6, 2026 | clinicaltrials |
| NCT05990465 | LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies | recruiting | Phase 1 | 12 | Medical College of WisconsinOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06090864 | ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells | recruiting | Phase 1 / Phase 2 | 31 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06533579 | Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) | recruiting | Phase 1 / Phase 2 | 32 | Vironexis Biotherapeutics Inc.INDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06609928 | FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 12 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07008118 | A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms | recruiting | Phase 1 | 120 | Incyte CorporationINDUSTRY | 5 | Aug 6, 2026 | clinicaltrials |
| NCT07518329 | Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.(SAPPHIRE) | not yet recruiting | Phase 1 | 46 | Arovella Therapeutics LtdINDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07749976 | GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 108 | VitruviaeINDUSTRY | 0 | Aug 6, 2026 | clinicaltrials |
| NCT02146924 | Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 | 71 | City of Hope Medical CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT02291848 | Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma(TACTAM) | active not recruiting | Phase 1 | 36 | Baylor College of MedicineOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT04281199 | TBI Using IMRT (VMAT or Tomotherapy) for the Prevention of Pul Toxicities in Patients Undergoing Donor SCT | active not recruiting | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05849207 | Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant(GeriBMT) | recruiting | Phase 1 | 26 | Ronald PaquetteOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06506643 | Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms | recruiting | Phase 1 / Phase 2 | 36 | Vector Vitale LLCINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06641648 | A Phase I Single-arm Clinical Study of Donor NK Cells Infusion Combined With Low-dose Interleukin-2 in the Treatment of Acute Myeloid Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation. | recruiting | Phase 1 | 12 | Peking University First HospitalOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06669247 | A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma(COSTIMM) | recruiting | Phase 1 / Phase 2 | 186 | Regeneron PharmaceuticalsINDUSTRY | 2 | Aug 5, 2026 | clinicaltrials |
| NCT06675123 | Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma | recruiting | Phase 1 | 10 | City of Hope Medical CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06177067 | Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | recruiting | Phase 1 | 24 | St. Jude Children's Research HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07742527 | A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care(DynaMMic-2) | not yet recruiting | Phase 1 | 22 | GlaxoSmithKlineINDUSTRY | 0 | Aug 3, 2026 | clinicaltrials |
| NCT03011814 | Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 78 | City of Hope Medical CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03091257 | A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma | active not recruiting | Phase 1 | 30 | Massachusetts General HospitalOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03696784 | Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma | active not recruiting | Phase 1 | 12 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04652960 | Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome | active not recruiting | Phase 1 | 38 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04847453 | Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis | active not recruiting | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05691491 | Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness | recruiting | Phase 1 / Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06708897 | A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies | recruiting | Phase 1 | 84 | Lomond Therapeutics Holdings, Inc.INDUSTRY | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06965114 | Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia | recruiting | Phase 1 / Phase 2 | 84 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07069699 | Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene | recruiting | Phase 1 / Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 10, 2026source: clinicaltrials